Karl-Anton Kreuzer

Status: Attending Physician
Address:

Clinic I of Internal Medicine
University Hospital Cologne
Kerpenerstr. 62
50937 Cologne

Phone: +49 221/478 97626
Fax: +49 221/478 97627
E-Mail: karl-anton.kreuzer@uni-koeln.de
Nationality: German

 

Education

1989-1996

Medical studies at the University of Bonn, Technical University of Munich, University of Zürich/Switzerland, University of Pittsburgh/USA

1997 University of Bonn Medical School, Bonn/Germany: M.D. exam & thesis
2004 Chamber of Physicians, Berlin/Germany: Board certification in Internal Medicine
2006

Habilitation at the Medical Faculty of the University at Cologne/Germany: ‘Molecular diagnostics in hematology’

 

Professional and Research Experience

1997-2004

Humboldt-University at Berlin, Charité Campus Virchow-Klinikum, Department of Medicine, Division of Hematalogy and Oncology (Prof. Dr. D. Huhn), Berlin/Germany: Registrar

2004-2008

University at Cologne, Department I of Internal Medicine (Prof. Dr. M. Hallek), Cologne/Germany: Senior Physician

2008-present

University at Cologne, Department I of Internal Medicine (Prof. Dr. M. Hallek), Cologne/Germany: Consultant Physician

Research focus

Professor and Chairman for Pathology, University of Cologne Research focus Molecular Pathology

 

Scientific Societies

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)

European Hematology Association (EHA)
American Association for Cancer research (AACR)
American Society for hematology (ASH)

 

Awardsand Prizes

DPC Academy, Bad Nauheim/Germany. Research Award: 'Molecular diagnostics in oncology and cancer research.' (2000)

 

List of the five most important publications

  1. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres M, Roboz G, Gaidano G, Scott B, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley L, Atallah E, Collins Jr R, Kantarjian H, Jabbour E, Azarnia N, Silverman LR. Results of a phase III trial of rigosertib in patients with myelodysplastic syndromes after failure of hypomethylating agents. Lancet Oncol 2016; in press

  2. Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014; 156: 590-602

  3. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110

  4. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B,  Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31: 3110-3118

  5. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert S, Pflueger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30: 3209-3216